Assessing risk: Does this patient have prostate cancer?

Journal of the National Cancer Institute

Volumn 98, Issue 8, 2006, Pages 506-507

  Carter, H Ballentine ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGE DISTRIBUTION; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SIZE; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; FAMILY HISTORY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RACE DIFFERENCE; RISK ASSESSMENT; BLOOD; NEEDLE BIOPSY; NOTE; PATHOLOGY; PREDICTION AND FORECASTING; PREVALENCE; PROSTATE TUMOR; RISK FACTOR; UNITED STATES; UNNECESSARY PROCEDURE;

BIOPSY, NEEDLE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNNECESSARY PROCEDURES;

EID: 33646447562     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj155     Document Type: Article

References (14)

1. U.S. Preventive Services Task Force. Available at http://www.ahcpr.gov/clinic/uspstf/uspsprca.htm#summary (2002).
2. Myrtle JF. Normal levels of prostate-specific antigen (PSA). In Clinical aspects of prostate cancer: Assessment of new diagnostic and management procedures. Edited by WJ Catalona, DS Coffey, JP Karr. New York, Elsevier; 1989. pp. 183-9.
3. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prosaic cancer. JAMA 1995;273:289-94.
4. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529-34.
5. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350: 2239-46.
6. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70.
7. Carter HB, Pearson JD, Metter JE, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
8. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351:125-35.
9. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376-83.
10. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for detection of curable prostate cancer. JAMA 1997;277:1456-60.
11. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996;276:1309-15.
12. Surveillance, Epidemiology, and End Results Fast Stats. Available at http://seer.cancer.gov/faststats/.
13. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: Lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94: 981-90.
14. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.